Dongli Liu is a postdoctoral researcher with extensive expertise in molecular and cell biology, including patient-derived primary cell culture and strong bioinformatics skills in next-generation sequencing (NGS). Since joining the Gynaecological Cancer Research Group at the University of New South Wales Sydney in 2018, Liu has led multiple research projects aimed at identifying prognostic biomarkers and novel therapies for ovarian and endometrial cancers. Her work has focused on developing patient-derived 3D cancer models to test novel therapies in molecular subtypes of malignancies.